Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevalence of New Psychoactive Substances Use

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03695419
Recruitment Status : Not yet recruiting
First Posted : October 4, 2018
Last Update Posted : October 5, 2018
Sponsor:
Information provided by (Responsible Party):
AAEsraa, Assiut University

Brief Summary:
According to the United Nations Office on Drugs and Crime [UNODC] World Drug Report, the annual prevalence of drug use seemed to be stable for the past few years. However, new psychoactive substances (NPS) have increased drastically in both supply and demand.Many NPS were discovered at the same time as other drugs, and it was simply, for whatever reasons, these other drugs became popular. The majority of these substances are chemicals produced by tweaking or altering the molecular structure of previous well-known psychoactive agents such as cannabis, cocaine, methylenedioxymeth-amphetamine (or MDMA, commonly known as ecstasy), and lysergic acid diethylamide (or LSD), which are being sold as "legal highs," "research chemicals," "herbal highs," "party pills," or "plant food" in an attempt to stay ahead of the law prohibiting the sale and use of psychoactive drugs.Substance abuse rates in Egypt have hit 10%, or double the global average. Tramadol is the most abused substance, followed by cannabis and heroin.In the past two years, two new drugs - known as Strox and Voodoo - have hit the Egyptian market.Voodoo is a combination of an aromatic plant, like marjoram or incense, which is infused with a synthetic cannabinoid that is up to 100 times as powerful as natural marijuana. Shabu is another name for methamphetamine hydrochloride, also known as crystal meth. Meth is a highly addictive stimulant that causes its user irreversible harm, physically and mentally. Pregabalin is increasingly being reported as possessing a potential for misuse.

Condition or disease
Addiction

  Show Detailed Description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Prevalence of New Psychoactive Substances Use Among Outpatient of Addiction Management Clinic in Assiut University Hospital
Estimated Study Start Date : January 1, 2019
Estimated Primary Completion Date : January 1, 2020
Estimated Study Completion Date : December 30, 2021

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. the prevalence of new psychoactive substance abuse among outpatient of addiction management clinic and patients admitted to addiction management unit of neurology and psychiatry department at Assiut university hospital. [ Time Frame: 2years ]

    All participant will subjected to the following:

    Special sheet designed for the study in department of neurology and psychiatry at Assiut University hospital asking about spychoactive substance use regarding to type, amount, duration,cause of use, and cause for stoppage.

    Addiction severity index Urinary drug screen




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
The study group comprised of Egyptians participants. Their age ranged between 18-60 years old, and both men and women are included. They fulfilled the criteria for substance abuse according to DSM-5 criteria. They were selected from the outpatient of addiction management clinic (either admitted to addiction management unit or not) of psychiatric unit of neurology and psychiatry department at Assiut university hospital.
Criteria

Inclusion Criteria:

  1. Patients diagnosed as substance dependence according to DSM-5 criteria.
  2. Aged between 18-60 years of both sex.
  3. Acceptance to participate in the study.

Exclusion Criteria:

  1. Chronic general medical conditions.
  2. Patients refused to participate at study
  3. History or current bipolar or psychotic disorder.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03695419


Contacts
Layout table for location contacts
Contact: Esraa A Abdel-regal, Doctor 00201033400846 seesoso30@yahoo.com
Contact: Romany H Gabrah, Lecurer 00201017714000 romany_hosny27@hotmail.com

Sponsors and Collaborators
Assiut University
Investigators
Layout table for investigator information
Principal Investigator: Romany H Gabrah Assiut U

Publications:
Layout table for additonal information
Responsible Party: AAEsraa, Princible investigator, Assiut University
ClinicalTrials.gov Identifier: NCT03695419     History of Changes
Other Study ID Numbers: PONPSUAOOAMCIAUH
First Posted: October 4, 2018    Key Record Dates
Last Update Posted: October 5, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Behavior, Addictive
Compulsive Behavior
Impulsive Behavior